Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Travere's FILSPARI reduced four IgA nephropathy biomarkers in new PROTECT data, adding evidence on kidney protection without proving disease modification.
Pharma & Biotech